A number of sclerosis medication nonetheless make up the biggest share of Biogen's complete gross sales, however Fampyra is the smallest contributor from this franchise. Quickly it received't contribute in any respect. Biogen, which is working to diversify past MS, is ending its partnership on the drug, the rights to which is able to revert to its developer, Acorda Therapeutics. […]